155 related articles for article (PubMed ID: 37422409)
21. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
Papamichael K; Chachu KA; Vajravelu RK; Vaughn BP; Ni J; Osterman MT; Cheifetz AS
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1580-1588.e3. PubMed ID: 28365486
[TBL] [Abstract][Full Text] [Related]
22. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.
Papamichael K; Stocco G; Ruiz Del Agua A
Ther Drug Monit; 2023 Oct; 45(5):579-590. PubMed ID: 37012629
[TBL] [Abstract][Full Text] [Related]
23. Anti-Tumor Necrosis Factor Alpha Therapeutic Drug Monitoring in Inflammatory Disease: A Systematic Review.
Schneider C; Stratman S; Choragudi S; Lev-Tov H
J Drugs Dermatol; 2023 May; 22(5):445-450. PubMed ID: 37133467
[TBL] [Abstract][Full Text] [Related]
24. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
Syversen SW; Jørgensen KK; Goll GL; Brun MK; Sandanger Ø; Bjørlykke KH; Sexton J; Olsen IC; Gehin JE; Warren DJ; Klaasen RA; Noraberg G; Bruun TJ; Dotterud CK; Ljoså MKA; Haugen AJ; Njålla RJ; Zettel C; Ystrøm CM; Bragnes YH; Skorpe S; Thune T; Seeberg KA; Michelsen B; Blomgren IM; Strand EK; Mielnik P; Torp R; Mørk C; Kvien TK; Jahnsen J; Bolstad N; Haavardsholm EA
JAMA; 2021 Dec; 326(23):2375-2384. PubMed ID: 34932077
[TBL] [Abstract][Full Text] [Related]
25. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
26. Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
Verhoef LM; van den Bemt BJ; van der Maas A; Vriezekolk JE; Hulscher ME; van den Hoogen FH; Jacobs WC; van Herwaarden N; den Broeder AA
Cochrane Database Syst Rev; 2019 May; 5(5):CD010455. PubMed ID: 31125448
[TBL] [Abstract][Full Text] [Related]
27. A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy.
Yao J; Jiang X; You JHS
Inflamm Bowel Dis; 2021 Jan; 27(2):275-282. PubMed ID: 32311018
[TBL] [Abstract][Full Text] [Related]
28. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease.
Fernandes SR; Bernardo S; Simões C; Gonçalves AR; Valente A; Baldaia C; Moura Santos P; Correia LA; Tato Marinho R
Inflamm Bowel Dis; 2020 Jan; 26(2):263-270. PubMed ID: 31247074
[TBL] [Abstract][Full Text] [Related]
29. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
Alsoud D; Moes DJAR; Wang Z; Soenen R; Layegh Z; Barclay M; Mizuno T; Minichmayr IK; Keizer RJ; Wicha SG; Wolbink G; Lambert J; Vermeire S; de Vries A; Papamichael K; Padullés-Zamora N; Dreesen E
Ther Drug Monit; 2024 Jun; 46(3):291-308. PubMed ID: 38648666
[TBL] [Abstract][Full Text] [Related]
30. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
31. Proactive versus Reactive Therapeutic Drug Monitoring: Why, When, and How?
Shmais M; Regueiro M; Hashash JG
Inflamm Intest Dis; 2022 Jan; 7(1):50-58. PubMed ID: 35224018
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review.
Marquez-Megias S; Nalda-Molina R; Sanz-Valero J; Más-Serrano P; Diaz-Gonzalez M; Candela-Boix MR; Ramon-Lopez A
Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631594
[TBL] [Abstract][Full Text] [Related]
33. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW;
Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1037-1053. PubMed ID: 29027257
[TBL] [Abstract][Full Text] [Related]
34. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
Syversen SW; Goll GL; Jørgensen KK; Sandanger Ø; Sexton J; Olsen IC; Gehin JE; Warren DJ; Brun MK; Klaasen RA; Karlsen LN; Noraberg G; Zettel C; Ljoså MKA; Haugen AJ; Njålla RJ; Bruun TJ; Seeberg KA; Michelsen B; Strand EK; Skorpe S; Blomgren IM; Bragnes YH; Dotterud CK; Thune T; Ystrøm CM; Torp R; Mielnik P; Mørk C; Kvien TK; Jahnsen J; Bolstad N; Haavardsholm EA
JAMA; 2021 May; 325(17):1744-1754. PubMed ID: 33944876
[TBL] [Abstract][Full Text] [Related]
35. Advantages of Proactive Therapeutic Drug Monitoring in a Prospective Cohort of Children With Inflammatory Bowel Disease Treated With Anti-Tumour Necrosis Factor.
Gasparetto M; Burgess N; Naik S; Studart D; Kadir A; Croft N; Sanderson I; Deb P
J Pediatr Gastroenterol Nutr; 2022 Apr; 74(4):484-489. PubMed ID: 35129158
[TBL] [Abstract][Full Text] [Related]
36. Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic Trial.
Bossuyt P; Pouillon L; Claeys S; D'Haens S; Hoefkens E; Strubbe B; Marichal D; Peeters H
J Crohns Colitis; 2022 Feb; 16(2):199-206. PubMed ID: 34297099
[TBL] [Abstract][Full Text] [Related]
37. Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis.
Iheozor-Ejiofor Z; Gordon M; Clegg A; Freeman SC; Gjuladin-Hellon T; MacDonald JK; Akobeng AK
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD013210. PubMed ID: 31513295
[TBL] [Abstract][Full Text] [Related]
38. Personalized Dosing of Infliximab in Patients With Inflammatory Bowel Disease Using a Bayesian Approach: A Next Step in Therapeutic Drug Monitoring.
Desai DC; Dherai AJ; Strik A; Mould DR
J Clin Pharmacol; 2023 Apr; 63(4):480-489. PubMed ID: 36458468
[TBL] [Abstract][Full Text] [Related]
39. Use of anti-TNF drug levels to optimise patient management.
Papamichael K; Cheifetz AS
Frontline Gastroenterol; 2016 Oct; 7(4):289-300. PubMed ID: 28839870
[TBL] [Abstract][Full Text] [Related]
40. Fecal transplantation for treatment of inflammatory bowel disease.
Imdad A; Nicholson MR; Tanner-Smith EE; Zackular JP; Gomez-Duarte OG; Beaulieu DB; Acra S
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012774. PubMed ID: 30480772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
